Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.43 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5802568 | 0.98 | LTA4H (0.55) | LTA4HPTGS2KCNA5KCNE1CYP2C19 | |
| Hydrochloric Acid SCHEMBL7399157 | 0.96 | LTA4H (0.54) | LTA4HPTGS2KCNA5KCNE1CYP2C19 | |
| SCHEMBL1680020 | 0.95 | LTA4H (0.51) | LTA4HPTGS2KCNA5KCNE1CYP2C19 | |
| SCHEMBL31143565 | 0.83 | LTA4H (0.71) | LTA4HPTGS2 | |
| SCHEMBL29550011 | 0.81 | LTA4H (0.61) | LTA4HPTGS2CYP2C19 | |
| SCHEMBL29969794 | 0.81 | LTA4H (0.61) | LTA4HPTGS2CYP2C19 | |
| SCHEMBL12301687 | 0.81 | LTA4H (0.73) | LTA4HPTGS2 | |
| SCHEMBL11034175 | 0.74 | LTA4H (0.50) | LTA4HPTGS2ALDH1A1 | |
| SCHEMBL29876575 | 0.74 | LTA4H (0.47) | LTA4HPTGS2KCNA5ALDH1A1SIGMAR1 | |
| SCHEMBL4515268 | 0.74 | KCNA5 (0.46) | LTA4HPTGS2KCNA5KCNE1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4438116-A | Quinoxalinyloxy-amino-propanol compounds with blood pressure lowering and β-blocking properties, their use and pharmaceutical compositions containing them | BOEHRINGER MANNHEIM GMBH (DE) | 1984-03-20 | — | — | US | claimed |
| EP-0019918-B1 | DERIVATIVES OF AMINO-PROPANOL, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1983-09-07 | — | — | EP | claimed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| EP-1711617-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTICS COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005064008-A9 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES INC (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005064008-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1509537-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003090690-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| EP-0019918-B1 | DERIVATIVES OF AMINO-PROPANOL, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1983-09-07 | — | — | EP | disclosed |
| US-4401820-A | IN THE PRESENCE OF AN ACYCLIC ACID AND AN ALDEHYDE; STABILITY | TANABE SEIYAKU CO., LTD. (JP) | 1983-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | PPA1, PPME1, PNP | LTA4H 1498/4885PTGS2 4129/4885KCNA5 4852/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | LTA4H 1533/4885PTGS2 4089/4885KCNA5 4825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.